Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joaquin Duato
- Full Time Employees
- 138,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1943
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
How To Build A $7,500 Monthly Paycheck Without Flipping A Single House
67 With $1.5 Million. Here Are My 3 Defensive Anchors
This Is the Dividend Portfolio That Pays Off Your Kid’s Student Loans
SpaceX Stock Is All Over the Place. 3 Dividend Stocks to Buy Instead That Will Let You Sleep Well at Night
3M maintains positive outlook for 2026 amid order momentum
Fed hawkishness and stretched valuations offset Iran deal relief, Deutsche Bank says
Don’t Wait For Your Rich Uncle To Die. Build Your Own Inheritance With This Portfolio
The Portfolio That Quietly Pays For Your Gasoline Forever
5 Dividend Stocks to Buy and Hold Forever
Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income
Pharma Momentum Fuels Johnson & Johnson's Path to Double-Digit Upside
The Dividend Growth Path That Turns $500,000 Into a Six-Figure Income Stream
This Dividend Portfolio Pays More Than Social Security and a Part-Time Job Combined
What a $2 Million Dividend Portfolio Actually Pays After Taxes in California
The $1 Million Retirement Mistake: Counting Income You’ll Never Get to Spend
The Retirement Portfolio That Forks Over a $10,000 Check Every Month
Smart Money Is Fleeing Tech for Johnson & Johnson Ahead of the Next Market Storm
Johnson & Johnson (JNJ) Could Be a Great Choice
If You Think The Market Will Ever Fall, Buy This